Non-Malignant Histiocytic Disorders of the Thorax: Typical ...
Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy
description
Transcript of Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy
![Page 1: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/1.jpg)
Histiocytic and dendritic cells neoplasms:
clinical behaviour and response to chemotherapy
Elena PalassiniIstituto Nazionale TumoriMilano
Stacchiotti S, Gentile A, Grosso F, Palassini E, Collini P, Bertulli R, Dileo P, Messina A, Morosi C, Gronchi A, Dei Tos
AP, Casali PG
![Page 2: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/2.jpg)
Background (1)
Histiocytic sarcoma (HS) Langherans cell sarcoma (LCS) Interdigitating dendritic cell sarcoma (IDCS) Follicular dendritic cell sarcoma (FDCS) Fibroblastic reticular cell tumor (FRCT) Unclassifiable dendritic cell tumor (UDCT)
Group of heterogeneous neoplasms showing differentiation toward accessory cells of immune system
![Page 3: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/3.jpg)
Background (2)
Surgery is felt to be the mainstay of treatment in localized presentations
The role of radiotherapy is undetermined Evidence of chemoresponsiveness to different regimens
(including CHOP, ABVD, DHAP, IE) is based on case reports and small case series, but the role of chemotherapy remains still undefined
![Page 4: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/4.jpg)
Patients and methods (1)
period 2002-2008 # pts 24 M/F 16/8 age: mean (range) yrs 45 (30-79) site: nodal/extranodal 12/12 stage at presentation:
Iocalized/locally advanced/metastatic 18/1/5
![Page 5: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/5.jpg)
g
UDC: 3 pts
Patients and methods (2)
LCS: 1HS: 5 IDCS: 4 FDCS: 11 UDCT: 3
Grade: low/high 8/16
![Page 6: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/6.jpg)
Patients and methods (3)
treatment (24):
surgery/radiotherapy/chemotherapy 19/10/12
![Page 7: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/7.jpg)
Results (1)
# pts 12 adjuvant/neoadjuvant/palliative 1/3/8 HS/LCS/IDCS/FDCS/UDCT 2/1/2/6/1
Front-line doxorubicin + cisplatin
![Page 8: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/8.jpg)
BIOPSY
wks -4 0 3 6
9
12 15 18
Pt 1, IDCS, localized disease
Dox+
DDP
Dox+
DDP
Dox+
DDP
Dox+
DDP
Dox+
DDP
SURGERY
RT
Treatment plan
9
![Page 9: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/9.jpg)
Baseline Dox + DDP x1
![Page 10: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/10.jpg)
Baseline Dox + DDP x3
HE
S-100
![Page 11: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/11.jpg)
Results (1)
evaluable for response 11 (HS/LCS/IDCS/FDCS/UDCS) (2/1/2/5/1)
PR RECIST (HS/LCS/IDCS/FDCS/UDCS) 8 (2/1/1/3/1)
SD RECIST ( HS/LCS/IDCS/FDCS/UDCS) 2 (0/0/1/1/0)
PD RECIST ( HS/LCS/IDCS/FDCS/UDCS) 1 (0/0/0/1/0)
■ consolidation with HD chemotherapy
and PBPC support 2
Front-line doxorubicin + cisplatin: activity
![Page 12: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/12.jpg)
Baseline Dox + DDP x6
Pt 2, HS
![Page 13: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/13.jpg)
Baseline Dox + DDP x6
![Page 14: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/14.jpg)
Pt 3, FDCS
Baseline Dox + DDP x4
Dox + DDP x6HD IFX x1
![Page 15: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/15.jpg)
Results (2)Dox + DDP: PFS in the palliative setting (8 pts)
PFS median 8 mos
PFS <6 mos 3 pts
FFP @30 mos 2 pts
![Page 16: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/16.jpg)
Results (3)
etoposide + ifosfamide 3
PR 2
PD 1 gemcitabine + vinorelbine 1
PR 1 gemcitabine 1
PR 1 high dose ifosfamide 2
PD 2
Further-line chemotherapy
![Page 17: Histiocytic and dendritic cells neoplasms : clinical behaviour and response to chemotherapy](https://reader035.fdocuments.net/reader035/viewer/2022081603/56815821550346895dc5877b/html5/thumbnails/17.jpg)
Conclusions
Small series, though among the largest in literature Doxorubicin + cisplatin is active in histiocitic and dendritic
cell neoplasms (RR 73%) All subtypes seem to be sensitive Response can be short-lasting (PFS <6 mos) and tumor
behaviour very aggressive Long PFS (PFS >30 mos) was observed in 3 metastatic
patients out of 8 Consolidation with high-dose chemotherapy is worth
testing Other drugs may be active (gemcitabine, gemcitabine and
vinorelbine, ifosfamide and etoposide)